Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 5;103(12):2026–2032. doi: 10.3324/haematol.2018.189787

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2018 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 3. — BCR-ABL1 transcript type and molecular response. (A) Comparison of the BCR-ABL1^IS values during the first two years of tyrosine kinase inhibitor (TKI) treatment (e13a2 shown in green and e14a2 shown in black). (B) Comparison of e13a2 and e14a2 BCR-ABL1 DNA values in the same patients. Diagnostic values were assigned a value of 100%. Note that at later time points the proportion of e14a2 patients with undetectable BCR-ABL1 DNA was higher than for e13a2, which may result in an underestimation of the difference between the two transcript types. (C) Box and whiskers plot comparing BCR-ABL1 expression ratio (mRNA:DNA) for e13a2 and e14a2 transcripts. *P<0.05; ***P<0.001.